Anti-Enolase-α Autoantibodies in Cancer-Associated Retinopathy: Epitope Mapping and Cytotoxicity on Retinal Cells
Open accessThe DOI matches its Crossref record.
Abstract
Patients with cancer-associated retinopathy syndrome (CAR), a progressive blinding disease related to retinal degeneration and systemic tumor outside the eye, develop autoantibodies against alpha-enolase. A small percentage of healthy subjects without evident tumor or visual symptoms also possess autoantibody against enolase. In these studies we examined the fine specificity of anti-enolase antibodies derived from patients with CAR and healthy individuals, using synthetic peptides covering the entire sequence of human alpha-enolase. Epitope mapping revealed that three binding regions of enolase within the residues 31-38 (FRAAVPSG), 176-183 (ANFREAMR), and 421-428 (AKFAGRNF) were common for all autoantibodies tested. However, pathogenic sera recognized an additional unique region, the sequence 56-63 (RYMGKGVS). There were also differences in in vitro cytotoxic activities on E1A.NR3 retinal cells and cell-death promoting activities between anti-enolase antibodies of healthy and CAR affected individuals. These studies showed that anti-enolase antibodies from patients with CAR were able to induce apoptotic cell death in E1A.NR3 retinal cells and provided a potential mechanism for retinal degeneration in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Multifunctional α-enolase: its role in diseases
Pancholi, V. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000910 · Cited by 838
Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy
Adamus, G., Ren, G., & Weleber, R. G. (2004) · BMC Ophthalmology · doi:10.1186/1471-2415-4-5 · Cited by 254
Self-citationParaneoplastic and non-paraneoplastic retinopathy and optic neuropathy: Evaluation and management
Rahimy, E., & Sarraf, D. (2013) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.09.001 · Cited by 206
Paraneoplastic Syndromes Affecting the Nervous System
Darnell, R. B., & Posner, J. B. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.03.008 · Cited by 177
Circulating anti-retinal antibodies as immune markers in age-related macular degeneration
Patel, N., Ohbayashi, M., Nugent, A. K., Ramchand, K., Toda, M., Chau, K., Bunce, C., Webster, A., Bird, A. C., Ono, S. J., et al. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02173.x · Cited by 125
Autoantibody-induced apoptosis as a possible mechanism of autoimmune retinopathy
Adamus, G. (2003) · Autoimmunity Reviews · doi:10.1016/s1568-9972(02)00127-1 · Cited by 102
Self-citationThe Role of Anti-α-Enolase Autoantibodies in Pathogenicity of Autoimmune-Mediated Retinopathy
MAGRYS, A., ANEKONDA, T., REN, G., & ADAMUS, G. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-006-9065-8 · Cited by 95
Self-citationAngeletti, A., Migliorini, P., Bruschi, M., Pratesi, F., Candiano, G., Prunotto, M., Verrina, E., & Ghiggeri, G. M. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102977 · Cited by 18
Metadata
- Authors
- Adamus, G., Amundson, D., Seigel, G. M., & Machnicki, M.
- Venue
- Journal of Autoimmunity
- Publisher
- Elsevier BV
- Published
- 1998-12
- Volume
- 11
- Issue
- 6
- Pages
- 671-677
- ISSN
- 0896-8411 (ISSN-L)
- OpenAlex
- W2072162133
- Cited by
- 119
- References
- 0
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.